{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:00Z","timestamp":1790516460317,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>STAT5 plays an important role in the transformation of hematopoietic cells by BCR-ABL. However, the downstream target genes activated by STAT5 in chronic myeloid leukemia (CML) cells remain largely unclear. Here, we investigated the mechanistic functional relationship between STAT5A-regulated microRNA and CML cell apoptosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of USP15, Caspase-6, STAT5A-regulated miR-202-5p and STAT5A was detected by qRT-PCR and Western blotting in CML cell lines and PBMCs of CML patients. Cell apoptosis was evaluated by flow cytometry. Both gain- and loss-of-function experiments were used to investigate the roles of USP15, miR-202-5p and STAT5A in CML. Luciferase reporter assay detected the effect of miR-202-5p on USP15 expression. Xenograft animal model was used to test the effect of anti-miR-202-5p and pimozide on K562 cell xenograft growth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>USP15 expression was significantly downregulated in CML cell lines and PBMCs of CML patients. Depletion of USP15 increased, whereas overexpression of USP15 reduced the resistance of CML cells to Imatinib. Further, decreased deubiquitinating activity of USP15 by USP15 downregulation led to reduced caspase-6 level, thus attenuating CML cell apoptosis. Mechanistically, miR-202-5p was upregulated in K562G cells and negatively regulated USP15 expression by directly targeting USP15 3\u2032-UTR. Correspondingly, upregulation of miR-202-5p enhanced the resistance of CML cells to Imatinib by inhibiting cell apoptosis. Importantly, STAT5A was upregulated in CML cells and directly activated miR-202-5p transcription by binding to the pre-miR-202 promoter. Pimozide induced CML cell apoptosis and significantly reduced K562 cell xenograft growth in vivo by blocking STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>we provide the first evidence that de-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses the apoptosis of CML cells, targeting this pathway might be a promising therapeutic approach for the treatment of CML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-019-1502-7","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T13:02:23Z","timestamp":1579266143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["De-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance"],"prefix":"10.1186","volume":"39","author":[{"given":"Zi-Yuan","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"issue":"10","key":"1502_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM199909023411016","volume":"341","author":"I Nash","year":"1999","unstructured":"Nash I. Chronic myeloid leukemia. N Engl J Med. 1999;341(10):765.","journal-title":"N Engl J Med"},{"issue":"10","key":"1502_CR2","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"12","key":"1502_CR3","first-page":"2589","volume":"13","author":"D Cortez","year":"1996","unstructured":"Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene. 1996;13(12):2589\u201394.","journal-title":"Oncogene"},{"issue":"2","key":"1502_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18(2):189\u2013218.","journal-title":"Leukemia"},{"issue":"19","key":"1502_CR5","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/onc.2016.424","volume":"36","author":"WT Liu","year":"2017","unstructured":"Liu WT, Huang KY, Lu MC, Huang HL, Chen CY, Cheng YL, Yu HC, Liu SQ, Lai NS, Huang HB. TGF-beta upregulates the translation of USP15 via the PI3K\/AKT pathway to promote p53 stability. Oncogene. 2017;36(19):2715\u201323.","journal-title":"Oncogene"},{"issue":"3","key":"1502_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm.2619","volume":"18","author":"PJ Eichhorn","year":"2012","unstructured":"Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A, et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat Med. 2012;18(3):429\u201335.","journal-title":"Nat Med"},{"issue":"1","key":"1502_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-018-03599-w","volume":"9","author":"A Padmanabhan","year":"2018","unstructured":"Padmanabhan A, Candelaria N, Wong KK, Nikolai BC, Lonard DM, O'Malley BW, Richards JS. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018;9(1):1270.","journal-title":"Nat Commun"},{"issue":"11","key":"1502_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s12276-018-0180-4","volume":"50","author":"L Zhou","year":"2018","unstructured":"Zhou L, Jiang H, Du J, Li L, Li R, Lu J, Fu W, Hou J. USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-kappaBp65. Exp Mol Med. 2018;50(11):151.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1502_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bbrc.2009.08.015","volume":"388","author":"M Xu","year":"2009","unstructured":"Xu M, Takanashi M, Oikawa K, Tanaka M, Nishi H, Isaka K, Kudo M, Kuroda M. USP15 plays an essential role for caspase-3 activation during paclitaxel-induced apoptosis. Biochem Biophys Res Commun. 2009;388(2):366\u201371.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"1502_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/ni.2885","volume":"15","author":"Q Zou","year":"2014","unstructured":"Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, et al. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 2014;15(6):562\u201370.","journal-title":"Nat Immunol"},{"issue":"4","key":"1502_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jmb.2009.06.066","volume":"391","author":"X Huang","year":"2009","unstructured":"Huang X, Langelotz C, Hetfeld-Pechoc BK, Schwenk W, Dubiel W. The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15. J Mol Biol. 2009;391(4):691\u2013702.","journal-title":"J Mol Biol"},{"issue":"11","key":"1502_CR12","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1093\/nar\/gkn271","volume":"36","author":"B Basham","year":"2008","unstructured":"Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, Lees E, Rascle A. In vivo identification of novel STAT5 target genes. Nucleic Acids Res. 2008;36(11):3802\u201318.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1502_CR13","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1182\/blood-2011-01-332569","volume":"117","author":"AG Turhan","year":"2011","unstructured":"Turhan AG. STAT5 as a CML target: STATinib therapies? Blood. 2011;117(12):3252\u20133.","journal-title":"Blood"},{"issue":"24","key":"1502_CR14","doi-asserted-by":"publisher","first-page":"20555","DOI":"10.18632\/oncotarget.4111","volume":"6","author":"NA Sibbesen","year":"2015","unstructured":"Sibbesen NA, Kopp KL, Litvinov IV, Jonson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-cell lymphoma. Oncotarget. 2015;6(24):20555\u201369.","journal-title":"Oncotarget"},{"key":"1502_CR15","doi-asserted-by":"publisher","first-page":"8928","DOI":"10.1038\/ncomms9928","volume":"6","author":"N Haetscher","year":"2015","unstructured":"Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, Bohnenberger H, Jung K, Schroeder T, Serve H, et al. STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling. Nat Commun. 2015;6:8928.","journal-title":"Nat Commun"},{"issue":"2","key":"1502_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690\u20138.","journal-title":"Blood"},{"key":"1502_CR17","doi-asserted-by":"crossref","unstructured":"Chou CK, Chang YT, Korinek M, Chen YT, Yang YT, Leu S, Lin IL, Tang CJ, Chiu CC. The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases. Int J Mol Sci. 2017;18(3).","DOI":"10.3390\/ijms18030483"},{"issue":"1","key":"1502_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2013.04.022","volume":"51","author":"NF Villeneuve","year":"2013","unstructured":"Villeneuve NF, Tian W, Wu T, Sun Z, Lau A, Chapman E, Fang D, Zhang DD. USP15 negatively regulates Nrf2 through deubiquitination of Keap1. Mol Cell. 2013;51(1):68\u201379.","journal-title":"Mol Cell"},{"issue":"3","key":"1502_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1006\/geno.1999.5879","volume":"59","author":"RT Baker","year":"1999","unstructured":"Baker RT, Wang XW, Woollatt E, White JA, Sutherland GR. Identification, functional characterization, and chromosomal localization of USP15, a novel human ubiquitin-specific protease related to the UNP oncoprotein, and a systematic nomenclature for human ubiquitin-specific proteases. Genomics. 1999;59(3):264\u201374.","journal-title":"Genomics"},{"issue":"10","key":"1502_CR20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/sj.cdd.4401065","volume":"9","author":"V Cowling","year":"2002","unstructured":"Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 2002;9(10):1046\u201356.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1502_CR21","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3892\/ol.2017.6628","volume":"14","author":"L Zhang","year":"2017","unstructured":"Zhang L, Li Y, Li X, Zhang Q, Qiu S, Zhang Q, Wang M, Xing H, Rao Q, Tian Z, et al. Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells. Oncol Lett. 2017;14(3):3862\u20138.","journal-title":"Oncol Lett"},{"issue":"16","key":"1502_CR22","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1073\/pnas.0508143103","volume":"103","author":"K Wagner","year":"2006","unstructured":"Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr\/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006;103(16):6338\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1502_CR23","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421\u20139.","journal-title":"Blood"},{"issue":"9","key":"1502_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29(9):1823\u201331.","journal-title":"Leukemia"},{"issue":"10","key":"1502_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, et al. Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"1502_CR26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/cncr.25717","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011;117(9):1800\u201311.","journal-title":"Cancer"},{"key":"1502_CR27","first-page":"359","volume":"14","author":"DP Flanigan","year":"1982","unstructured":"Flanigan DP, Williams LR. Venous insufficiency of the lower extremities: new methods of diagnosis and therapy. Surg Annu. 1982;14:359\u201380.","journal-title":"Surg Annu"},{"issue":"Supplement 1","key":"1502_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2018-99-113960","volume":"132","author":"Lin Tong","year":"2018","unstructured":"Tong L, Xu N, Zhou X, Huang JX, Wu WE, Chen C, Liang L, Liu QF, Liu XL. PKM2 mediates chronic myeloid leukemia Imatinib resistance by regulating glycolysis energy metabolism. Blood. 2018;132.","journal-title":"Blood"},{"issue":"1","key":"1502_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79(1):13\u201321.","journal-title":"Cell"},{"issue":"8","key":"1502_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10(8):550\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"19","key":"1502_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/onc.2011.443","volume":"31","author":"JM Fraile","year":"2012","unstructured":"Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31(19):2373\u201388.","journal-title":"Oncogene"},{"issue":"11","key":"1502_CR32","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/leu.2015.90","volume":"29","author":"D Inoue","year":"2015","unstructured":"Inoue D, Nishimura K, Kozuka-Hata H, Oyama M, Kitamura T. The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination. Leukemia. 2015;29(11):2257\u201360.","journal-title":"Leukemia"},{"issue":"1","key":"1502_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1078-0432.CCR-18-1740","volume":"25","author":"Q Jin","year":"2019","unstructured":"Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, Johnson MR, Volk AG, Wang F, Wu J, et al. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T-cell leukemia. Clin Cancer Res. 2019;25(1):222\u201339.","journal-title":"Clin Cancer Res"},{"key":"1502_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41421-019-0092-z","volume":"5","author":"Y Liao","year":"2019","unstructured":"Liao Y, Liu N, Xia X, Guo Z, Li Y, Jiang L, Zhou R, Tang D, Huang H, Liu J. USP10 modulates the SKP2\/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discov. 2019;5:24.","journal-title":"Cell Discov"},{"issue":"2","key":"1502_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"17","key":"1502_CR36","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1056\/NEJMp058190","volume":"353","author":"CZ Chen","year":"2005","unstructured":"Chen CZ. MicroRNAs as oncogenes and tumor suppressors. New Engl J Med. 2005;353(17):1768\u201371.","journal-title":"New Engl J Med"},{"issue":"12","key":"1502_CR37","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/onc.2016.330","volume":"36","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ou Z, Sun Y, Yeh S, Wang X, Long J, Chang C. Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p\/USP13\/MITF\/AXL signals. Oncogene. 2017;36(12):1644\u201354.","journal-title":"Oncogene"},{"issue":"5","key":"1502_CR38","first-page":"6947","volume":"15","author":"S Zhou","year":"2018","unstructured":"Zhou S, Xiong M, Dai G, Yu L, Zhang Z, Chen J, Guo W. MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1. Oncol Lett. 2018;15(5):6947\u201356.","journal-title":"Oncol Lett"},{"issue":"1","key":"1502_CR39","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1038\/s41598-017-04368-3","volume":"7","author":"Z Wang","year":"2017","unstructured":"Wang Z, Yang J, Di J, Cui M, Xing J, Wu F, Wu W, Yang H, Zhang C, Yao Z, et al. Downregulated USP3 mRNA functions as a competitive endogenous RNA of SMAD4 by sponging miR-224 and promotes metastasis in colorectal cancer. Sci Rep. 2017;7(1):4281.","journal-title":"Sci Rep"},{"issue":"12","key":"1502_CR40","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4161\/cc.25116","volume":"12","author":"W Warsch","year":"2013","unstructured":"Warsch W, Grundschober E, Sexl V. Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle. 2013;12(12):1813\u20134.","journal-title":"Cell Cycle"},{"issue":"12","key":"1502_CR41","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12):3409\u201320.","journal-title":"Blood"},{"issue":"1","key":"1502_CR42","first-page":"455","volume":"41","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, Xu X. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib. Int J Mol Med. 2018;41(1):455\u201363.","journal-title":"Int J Mol Med"},{"issue":"18","key":"1502_CR43","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1016\/j.bmcl.2014.07.069","volume":"24","author":"R Rondanin","year":"2014","unstructured":"Rondanin R, Simoni D, Romagnoli R, Baruchello R, Marchetti P, Costantini C, Fochi S, Padroni G, Grimaudo S, Pipitone RM, et al. Inhibition of activated STAT5 in Bcr\/Abl expressing leukemia cells with new pimozide derivatives. Bioorg Med Chem Lett. 2014;24(18):4568\u201374.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1502-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:20:33Z","timestamp":1610756433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1502-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"8 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was authorized Ethics Committee of Second Hospital of Hebei Medical University. All patients and volunteers were anonymous and provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}